Sort
261,768 grants matching “gene therapy”
Mechanisms of Effective Humoral Immune Responses to HIV-1
$1,230,841Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Extending the Phenotype of Nonsyndromic Orofacial Clefts
$1,230,712Mary L Marazita · University Of Pittsburgh At Pittsburgh · R01 · FY2010 · DE
Rapid multiplex method for direct phenotypic ID/AST of bacterial pathogens
$1,230,698David A Schofield · Guild Associates, Inc. · R01 · FY2018 · AI
P01-Pathogenesis and Prevention of Osteoporosis
$1,230,647University Of Connecticut Sch Of Med/Dnt · P01 · FY2003 · AR
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit
$1,230,515Pablo Tebas · University Of Pennsylvania · UM1 · FY2016 · AI
Clinical, Immunological and Genetic Analyses of ALPS and Related Immunedysregulatory Disorders
$1,230,412V Koneti Rao · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Primary Immune Deficiency Clinic
$1,230,412Alexandra Freeman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
From therapeutic mechanisms to unraveling the pathophysiology of MS
$1,230,411Bibiana Bielekova · National Institute Of Neurological Disorders And Stroke · ZIA · FY2011 · NS
University of Iowa Hawkeye Intellectual and Developmental Disabilities Research Center (Hawk-IDDRC)
$1,230,243Lane Strathearn · University Of Iowa · P50 · FY2021 · HD
Development of a universal gene therapy for hemophilia A or B with or without inhibitors
$1,230,198Paris Margaritis · Geneventiv Therapeutics, Inc. · R44 · FY2024 · HL
Research Center for Pharmacology and Drug Toxicology
$1,230,188Vanderbilt University · P50 · FY2004 · GM
DF/HCC Kidney Cancer SPORE (supplement)
$1,230,080David McDermott · Beth Israel Deaconess Medical Center · P50 · FY2025 · CA
MSK SPORE in Genomic Instability in Breast Cancer
$1,230,080Simon N Powell · Sloan-Kettering Inst Can Research · P50 · FY2025 · CA
NYU Melanoma SPORE
$1,230,080Iman Osman · New York University School Of Medicine · P50 · FY2025 · CA
Structural profiling of tauopathy seeds
$1,230,000Lukasz A. Joachimiak · Ut Southwestern Medical Center · RF1 · FY2023 · AG
An unbiased OMICs approach to identify mechanisms of Cocaine regulation of the HIV reservoir.
$1,229,898Rafick-Pierre Sekaly · Case Western Reserve University · R01 · FY2016 · DA
Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis
$1,229,878William James Adams · Riparian Pharmaceuticals, Inc. · R44 · FY2017 · HL
RHESUS PROPAGATION BY INTRACYTOPLASMIC NUCLEAR INJECTION
$1,229,832Magee-Women'S Res Inst And Foundation · R24 · FY2004 · RR
ONCOGENES, PROTO-ONCOGENES AND RETROVIRAL VECTORS
$1,229,331Salk Institute For Biological Studies · R35 · FY2000 · CA
NIDCD Core for Clinical Research and Care
$1,229,289Carter Van Waes · National Institute On Deafness And Other Communication Disorders · ZID · FY2013 · DC
Intracellular In vivo Imaging
$1,229,175Peter L. Choyke · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial
$1,229,055Nisha Acharya · University Of California, San Francisco · UG1 · FY2023 · EY
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture
$1,229,027Harshini Neelakantan · Ridgeline Therapeutics, Llc · U44 · FY2021 · AG
Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma
$1,228,902Colleen Doyle Cooper · Celdara Medical, Llc · R44 · FY2025 · CA
Immunobiology of Tolerance FF Allogeneic Hematopoietic Cell Transplantation
$1,228,777John Andrew Hansen · Fred Hutchinson Cancer Research Center · P01 · FY2012 · AI